Pharsight

Jentadueto Xr patents expiration

JENTADUETO XR's oppositions filed in EPO
JENTADUETO XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6340475 BOEHRINGER INGELHEIM Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(7 years ago)

US6635280 BOEHRINGER INGELHEIM Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(7 years ago)

US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6488962 BOEHRINGER INGELHEIM Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Jun, 2020

(3 years ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(10 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(10 months ago)

US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 4 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 5 months from now)

US8883805

(Pediatric)

BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
May, 2026

(1 year, 11 months from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(2 years from now)

US9173859

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
Nov, 2027

(3 years from now)

US8673927

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
Nov, 2027

(3 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10022379

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US9415016

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US11911388 BOEHRINGER INGELHEIM Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
Apr, 2030

(5 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(5 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(5 years from now)

US9155705

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Nov, 2030

(6 years from now)

US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Mar, 2033

(8 years from now)

US9555001

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Sep, 2033

(9 years from now)

Jentadueto Xr is owned by Boehringer Ingelheim.

Jentadueto Xr contains Linagliptin; Metformin Hydrochloride.

Jentadueto Xr has a total of 27 drug patents out of which 9 drug patents have expired.

Expired drug patents of Jentadueto Xr are:

  • US6340475
  • US6635280
  • US6303661
  • US6890898
  • US7459428
  • US7078381
  • US6488962
  • US8178541
  • US8119648

Jentadueto Xr was authorised for market use on 27 May, 2016.

Jentadueto Xr is available in tablet, extended release;oral dosage forms.

Jentadueto Xr can be used as use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin, method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea, method of treating type 2 diabetes, linagliptin (5 mg daily dose) and metformin (with or without insulin) for treating type 2 diabetes patients with renal impairment and insufficient glycemic control despite previous treatment with metformin alone or in combination with insulin, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor, method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin.

The generics of Jentadueto Xr are possible to be released after 06 September, 2033.

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of treating type 2 diabetes; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dip...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage

JENTADUETO XR family patents

Family Patents